netFormulary NHS
Birmingham, Sandwell, Solihull and environs APC Formulary
Maintained by Midlands and Lancashire Commissioning Support Unit
 Search
 Formulary Chapter 11: Eye - Full Chapter
Notes:

 Criteria for Preservative Free (PF) and Single Dose Unit (SDU) presentations:

These are restricted to patients with
• true preservative allergy
and/or
• evidence of epithelial toxicity from preservatives
and/or
• severe dry eyes
and/or
• require/ may require surgery in the near future
and/or
• neonates

 Details...
11.08.02  Expand sub section  Ocular diagnostic and peri-operative preparations and photodynamic treatment
11.08.02  Expand sub section  Ocular diagnostic preparations
11.08.02  Expand sub section  Ocular peri-operative drugs
11.08.02  Expand sub section  Subfoveal choroidal neovascularisation
Aflibercept (Eylea®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
  • Use in line with NICE 
  • Link  NICE TA 486: Aflibercept for treating choroidal neovascularisation
    Link  NICE TA409: Visual impairment caused by macular oedema after branch retinal vein occlusion- aflibercept.
    Link  NICE TA346: Macular oedema (diabetic)- aflibercept
    Link  NICE TA305: Macular oedema (retinal vein occlusion)- aflibercept
    Link  NICE TA294: Macular degeneration (wet age-related) - aflibercept
       
    Bevacizumab intravitreal injection (Avastin®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
       
    Ranibizumab (Lucentis®)
    View adult BNF View SPC online View childrens BNF
    Restricted Drug Restricted
    Red
    High Cost Medicine
  • Use in line with NICE 
  • Link  NICE TA155: Age-related Macular Degeneration- ranibizumab
    Link  NICE TA274: Macular oedema (diabetic) - ranibizumab
    Link  NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance
    Link  NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab
       
    Verteporfin (Visudyne®)
    View adult BNF View SPC online View childrens BNF
    Restricted Drug Restricted
    Red
     
    Link  NICE guideline [NG82] Age-related macular degeneration
       
    11.08.02  Expand sub section  Vitreomacular traction to top
     ....
     Non Formulary Items
    Pegaptanib Sodium  (Macugen®)

    View adult BNF View SPC online View childrens BNF
    Non Formulary
    Link  NICE TA155: guidance on pegaptanib in AMD (August 2008)
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to children's BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Prescribing in children

    The APC notes that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications (‘off-label’ use) is often necessary in paediatric practice.

    The APC advises GPs to consider specialist prescribing recommendations for Green and Amber medicines that are not subject to ESCAs or RICaDs in combination with the information provided in the BNFC which goes beyond that of marketing authorisations. The BNFC has been designed for rapid reference and the information presented has been carefully selected to aid decisions on prescribing.
      

    Green

    Medicines suitable for routine use within primary care. Initiation and maintenance of prescribing by Specialists, GPs and other qualified clinicians.   

    Amber Initiation

    Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry.  

    Amber Recommended

    Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.  

    Amber SC

    Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry.  

    Red

    Medicines for initiation and maintenance prescribing by Specialists only.  

    Black

    Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use.  

    Grey

    Positive NICE TA and/or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information.  

    The term 'Specialist' refers to Consultants, General Practitioners and Independant Prescribers with a Specialist Interest.  

    netFormulary